Amid market volatility, these three companies offering yields above 4% present a compelling case for income-focused investors, backed by strategic pivots and resilient business models.
The long-term strategic partnership will leverage IQVIA's data-as-a-service platform to unify and streamline commercial data across 59 countries, aiming to accelerate product launches and enhance decision-making for the pharmaceutical giant.
A dramatic surge in SuperX AI Technology's share price has spotlighted its concentrated ownership structure, with private companies holding a dominant 34% stake and reaping the largest rewards from the recent rally. As the AI-driven healthcare sector heats up, investor attention turns to who holds the reins at this promising but closely held firm.
Eli Lilly commits $85 million upfront and over $1.8 billion in potential milestones to partner with Repertoire Immune Medicines, aiming to develop a new class of 'tolerizing' therapies that reset the immune system without broad suppression.
At its Analyst Day, Korro Bio detailed its lead candidate KRRO-121, an RNA-editing therapeutic designed to tackle hyperammonemia in urea cycle disorders and hepatic encephalopathy by stabilizing a key liver enzyme, positioning it as a potential paradigm shift from current burdensome treatments.
Citizens reiterates a 'Market Outperform' rating and $396 price target for BeOne Medicines (ONC), driven by robust Phase 3 trial results in gastric cancer. The firm highlights the company's strong pipeline and cash position as key growth drivers.
Shares of antibody discovery firm AbCellera Biologics plunged 16.8% last week, reigniting debate over its true worth. While a discounted cash flow model suggests deep undervaluation, its sky-high price-to-sales ratio paints a starkly different picture, leaving investors to navigate conflicting signals in a volatile biotech market.
Bank of America has raised its price target for clinical-stage biopharma firm Xencor (XNCR), highlighting a cautiously improving landscape for the sector driven by data catalysts, M&A, and capital access.
GSK makes a dual strategic move, acquiring RAPT Therapeutics for its food allergy portfolio and securing broader European approval for its RSV vaccine Arexvy, reinforcing its focus on immunology and respiratory health.
Cardinal Health (CAH) stock has drawn renewed investor interest following robust financial results, with revenue topping $234 billion and net income near $1.6 billion. The healthcare distributor's shares have rallied over 66% in the past year, though its premium valuation compared to peers is sparking debate among analysts.
Regeneron Pharmaceuticals' shares have softened in recent weeks, lagging behind broader market gains. A deep dive into valuation metrics, including DCF analysis and P/E ratios, suggests the biotech giant may be significantly undervalued. We examine the numbers behind the headlines and what they mean for investors.
Target is launching its largest-ever spring beauty collection, introducing over 3,000 new, predominantly budget-friendly items alongside redesigned in-store experiences and key leadership appointments, signaling a major strategic push to capture market share in the lucrative beauty sector.
